Table 2.
HCC versus non-HCC patients: clinical, pathological, and follow-up characteristics.
| HCC | Non-HCC | P value | |
|---|---|---|---|
| Patients | 63 | 67 | |
| Age (±SDa) (range) years | 55.0 ± 14.4 (18–85) | 47.5 ± 13.8 (21–88) | <0.01 |
| Male/female | 18/45 | 21/46 | NS* |
| Tumour size (±SDa) (range) mm | 32.4 ± 18.9 (6–100) | 25.6 ± 13.5 (5–65) | <0.05 |
| Distant metastasis at diagnosis | 1 | 3 | NS* |
| pT stage | |||
| T1/T2/T3 | 14/30/19 | 22/33/12 | NS* |
| pN stage | |||
| NX/N0/N1 | 62/0/1 | 67/0/0 | NS* |
| pM stage | |||
| M0/M1 | 62/1 | 64/3 | NS* |
| MI/WI | 25/38 | 41/26 | <0.05 |
| Multifocal disease | 3 | 1 | NS* |
| Microcarcinoma | 4 | 3 | NS* |
| Concomitant PTC | 8 | 13 | NS* |
| Follow-up yes/no | 58/5 | 59/8 | NS* |
| Follow-up (±SDa) (range) months | 101.9 ± 44.6 (17–179) | 104.8 ± 34.8 (29–174) | NS* |
| RAI/no RAI | 55/3 | 50/9 | NS* |
| Distant metastasis at follow-up | 3 | 0 | NS* |
SDa: standard deviation; NS*: not significant.